Lialda for ulcerative colitis

Share this content:
The FDA has approved Lialda (mesalamine), a once-daily oral formulation of mesalamine for the induction of remission in patients with active, mild-to-moderate ulcerative colitis. Lialda tablets have a pH dependent gastro-resistant coating which delays the release of the medication to the colon. Lialda is expected to be available soon. For more information call Shire at (800) 536-7878 or visit
You must be a registered member of Clinical Advisor to post a comment.

2018 Upcoming Meetings

Sign Up for Free e-newsletters